Development status: Approved, off-patent

Gram-negative activity

Mechanism of Action/Target pathogen: Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-negative bacteria

Additional information: Semisynthetic, derived from sisomicin. Primarily used for topical application